(Il Sole 24 Ore Radiocor) - Milano, 27 apr - The US pharmaceutical group Eli Lilly said that it has entered a definitive agreement to buy Ajax Therapeutics, a US biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms.

Under the terms of the agreement, Ajax shareholders could receive up to 2.3 billion in dollars, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

Ajax's lead asset, AJ1-11095, is an investigational, once-daily oral, first-in-class Type II JAK2 inhibitor currently being evaluated in a phase 1 clinical trial, AJX-101, in patients with myelofibrosis who have previously.

been treated with a Type I JAK2 inhibitor.

(RADIOCOR) 27-04-26 13:43:04 (0317) 5 NNNN